Tags : Pre-Exposure Prophylaxis

Gilead Reports Updated Results of Descovy in P-III DISCOVER Study

Tuba Khan July 24, 2019

Shots: The P-III DISCOVER study involves assessing of Descovy (emtricitabine, 200 mg/tenofovir alafenamide, 25 mg, qd) vs Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in adult male and transgender […]readmore

Tags : Pre-Exposure Prophylaxis

Gilead Reports Updated Results of Descovy in P-III DISCOVER Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Pre-Exposure Prophylaxis

﻿Gilead Reports Updated Results of Descovy in P-III DISCOVER Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Gilead Reports Updated Results of Descovy in P-III DISCOVER Study